Collaboration Agreements (Details) - USD ($)	1 Months Ended		12 Months Ended
	Feb. 27, 2025	Jan. 31, 2022	Dec. 31, 2024	Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 9,434,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable			$ 1,667,500,000
Percentage of option to co-fund development costs upon achievement of certain milestones			50.00%
Milestone Payment Received		$ 15,000,000
Milestone Payment Received in Cash		6,750,000
Milestone Payment Received in Equity Investment		8,250,000
Equity investment measure at fair value		7,876,000
Premium		374,000
Performance obligation related to milestone		0
Revenue		$ 6,750,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments	$ 7,500,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable			$ 1,067,500,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Sales Based Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable			$ 600,000,000